New dengue treatments are required to keep up with the evolving dengue threat, which some fear could hit Europe and the US. As the Asian tiger mosquito spreads the disease to colder climes, the co-founders of Effecta Pharma explain their efforts to tackle the problem today.
The extent to which dengue infection has advanced over the past few decades has been phenomenal. Most of this spread has been down to the Aedes aegypti mosquito. This primary dengue vector thrives in tropical and sub-tropical climates but struggles to survive in cooler temperatures.
While we’ve previously raised concerns about how climate change might allow this vector to spread further afield in the future, we haven’t considered the threat from its cousin and secondary dengue vector: Aedes albopictus.